← All themes

Immunotherapy & Oncology

Cancer treatment has moved from poisoning dividing cells towards directing the immune system at the tumour, and towards drugs that carry their payload only to cancerous tissue. It absorbs more drug development spending than any other area.

388 stocks

#	Name	Funds holding	Growth	Growth %	Fund value
1	1 Johnson & Johnson JNJ $612B	2,229	-5	-0.2%	$213B
2	2 Pfizer PFE $166B	1,964	-29	-1%	$145B
3	3 Merck MRK $364B	1,815	+53	+3%	$129B
4	4 AbbVie ABBV $501B	1,654	+18	+1%	$70.1B
5	5 Gilead Sciences GILD $190B	1,561	-38	-2%	$78.8B
6	6 Bristol-Myers Squibb BMY $121B	1,523	-54	-3%	$63.8B
7	7 Amgen AMGN $230B	1,518	+44	+3%	$99.2B
8	8 Novartis NVS $279B	877	-2	-0.2%	$18.7B
9	9 GSK GSK $95.9B	742	0	0%	$9.13B
10	10 Regeneron Pharmaceuticals REGN $80.1B	555	+13	+2%	$29.6B
11	11 AstraZeneca AZN $251B	451	+53	+13%	$10.9B
12	12 Incyte INCY $22.6B	399	+28	+8%	$16.5B
13	13 Jazz Pharmaceuticals JAZZ $13.6B	327	-40	-11%	$6.5B
14	14 Opko Health OPK $1.02B	270	+25	+10%	$1.35B
15	SGEN 15 DELISTED Seagen Inc. Common Stock SGEN	242	+28	+13%	$7.53B
16	16 DELISTED Exact Sciences EXAS	225	+44	+24%	$1.77B
17	17 Myriad Genetics MYGN $397M	224	-29	-11%	$1.7B
18	18 DELISTED Assertio ASRT	204	-3	-1%	$1.57B
19	19 Exelixis EXEL $15.1B	204	+38	+23%	$2.81B
20	20 DELISTED Radius Health, Inc. RDUS	171	+29	+20%	$2.27B
21	21 Precigen PGEN $2.63B	169	0	0%	$2.82B
22	CLVS 22 DELISTED Clovis Oncology, Inc. CLVS	163	+41	+34%	$1.41B
23	23 Halozyme HALO $13.3B	162	+1	+0.6%	$1.28B
24	24 DELISTED Immunogen Inc IMGN	156	-2	-1%	$202M
25	25 Puma Biotechnology PBYI $527M	149	+39	+35%	$2.01B